

biopharmaceutical company with a
pipeline of selective oral immunology
therapies focused on treating chronic
inflammatory and autoimmune diseases.
Selective
Oral Drugs in
Immunology


small molecule products: lead development
program, vidofludimus calcium (IMU-838), is a
selective DHODH inhibitor; IMU-935 is a
selective inverse agonist of RORγt; and IMU-856
targets the restoration of the intestinal
barrier function.
Products in
Clinical
Development


orally available treatment options with sound
therapeutic efficacy and outstanding safety
and tolerability available to multiple sclerosis
patients, thereby improving the quality
of their lives.
MS Patients New,
Safe & Easy-to-Use Treatment Options


well-tolerated treatment options to patients
suffering from ulcerative colitis and other
gastrointestinal disorders in order to improve
patients’ lives by eliminating the debilitating
side effects of these diseases.
Convenient,
Oral Treatment
Options Available
to IBD Patients
Press Releases & Events
Latest News.
Questions?
Get in touch.
Immunic, Inc. (Nasdaq: IMUX) Stock Quote: